384 related articles for article (PubMed ID: 29424257)
21. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
22. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
Liu C; Kuang X; Li K; Guo X; Deng Q; Li D
Food Funct; 2020 Dec; 11(12):10817-10827. PubMed ID: 33237064
[TBL] [Abstract][Full Text] [Related]
23. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
[TBL] [Abstract][Full Text] [Related]
24. Romosozumab in postmenopausal women with low bone mineral density.
McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
[TBL] [Abstract][Full Text] [Related]
25. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
26. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Shen J; Ke Z; Dong S; Lv M; Yuan Y; Song L; Wu K; Xu K; Hu Y
Med Sci Monit; 2022 Apr; 28():e935491. PubMed ID: 35430576
[TBL] [Abstract][Full Text] [Related]
28. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
Nealy KL; Harris KB
Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
[TBL] [Abstract][Full Text] [Related]
29. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
[TBL] [Abstract][Full Text] [Related]
30. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.
Wang YK; Qin SQ; Ma T; Song W; Jiang RQ; Guo JB; Li K; Zhang YM
Medicine (Baltimore); 2017 May; 96(21):e6970. PubMed ID: 28538396
[TBL] [Abstract][Full Text] [Related]
31. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Brown JP; Engelke K; Keaveny TM; Chines A; Chapurlat R; Foldes AJ; Nogues X; Civitelli R; De Villiers T; Massari F; Zerbini CAF; Wang Z; Oates MK; Recknor C; Libanati C
J Bone Miner Res; 2021 Nov; 36(11):2139-2152. PubMed ID: 34190361
[TBL] [Abstract][Full Text] [Related]
32. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
[TBL] [Abstract][Full Text] [Related]
33. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.
Cranney A; Tugwell P; Zytaruk N; Robinson V; Weaver B; Shea B; Wells G; Adachi J; Waldegger L; Guyatt G;
Endocr Rev; 2002 Aug; 23(4):540-51. PubMed ID: 12202469
[TBL] [Abstract][Full Text] [Related]
34. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
[TBL] [Abstract][Full Text] [Related]
35. The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
Xu F; Wang Y; Zhu X
Clin Ther; 2024 Mar; 46(3):267-274. PubMed ID: 38307725
[TBL] [Abstract][Full Text] [Related]
36. Romosozumab: A Review in Postmenopausal Osteoporosis.
Paik J; Scott LJ
Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
[TBL] 
